Literature DB >> 2972421

Enzyme-linked immunosorbent assay of lipoprotein(a) in serum and cord blood.

A Abe1, S Maeda, K Makino, M Seishima, K Shimokawa, A Noma, M Kawade.   

Abstract

We have developed a new sensitive method for quantifying lipoprotein(a) (Lp(a] in human serum, using a 'sandwich' type noncompetitive enzyme-linked immunosorbent assay (ELISA). The solid-phase used was a polystyrene plate. The anti-Lp(a) antibody-enzyme conjugate was labelled by linking Fab' fragments to peroxidase (EC 1.11.1.7) by the maleimide method. The minimum detectable concentration was 0.5 ng/well. Routinely, the assay was carried out with 1,000-fold diluted serum, and Lp(a) was quantified between 4.0 and 500 mg/l. Within-run coefficients of variation (CVs) ranged from 3.5% to 10.4% and between-run CVs from 5.0% to 11.1%. Results by the ELISA were in good agreement with those by radial immunodiffusion (r = 0.955). The distribution of Lp(a) in serum from 820 healthy donors was highly skewed: mean 141.1 mg/l, medium 97.9 mg/l. In cord blood, the mean and median were 15.6 and 9.8 mg/l, respectively. This ELISA for Lp(a) has the advantages of being highly sensitive and specific, simple to perform, and does not use radioisotopes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2972421     DOI: 10.1016/0009-8981(88)90304-x

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  4 in total

1.  Increased concentrations of serum Lp(a) lipoprotein in patients with primary gout.

Authors:  S Takahashi; T Yamamoto; Y Moriwaki; Z Tsutsumi; K Higashino
Journal:  Ann Rheum Dis       Date:  1995-02       Impact factor: 19.103

2.  Combined therapy with probucol and pravastatin in hypercholesterolaemia. One year follow-up study.

Authors:  K Saku; B Zhang; K Hirata; Y Okura; H Bai; R Liu; K Arakawa
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

3.  Serum lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in the families of NIDDM patients.

Authors:  K Hirata; K Saku; S Jimi; S Kikuchi; H Hamaguchi; K Arakawa
Journal:  Diabetologia       Date:  1995-12       Impact factor: 10.122

4.  High-density lipoprotein and apolipoprotein A-I deficiency induced by combination therapy with probucol and bezafibrate.

Authors:  K Saku; B Zhang; S Jimi; H Bai; K Hirata; N Sasaki; R Liu; K Arakawa
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.